San Francisco, June 13th, 2019 – Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that its Phase 2 study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction is now enrolling and recruiting in all multiple European and US centers.
The clinical study is intended to evaluate the safety and efficacy of Recardio’s lead candidate dutogliptin to restore lost myocardial function in patients who experience STEMI, a severe form of heart attack, and receive percutaneous coronary intervention with stent placement. Specialized cardiology centers located throughout Europe and US have enrolled patients and are meanwhile actively recruiting. Roman Schenk, Recardio’s President, remarked that the enrollment of all planned 140 patients will proceed until end of 2019 such that outcomes will be available in early 2020.
Recardio’s regenerative therapeutic approach to minimize and repair the heart muscle injury that follows an infarction consists of mobilizing, recruiting, and homing stem cells in-vivo by using cytokines and inhibitors. Specifically, engraftment and an improvement in cardiac output are possible by mobilizing bone marrow stem cells into circulating blood with G-CSF and then initiating stem cell migration and homing to cardiac sites of ischemia or injury with dutogliptin, a small molecule inhibitor of dipeptidylpeptidase-IV (DPP4), the key enzyme responsible for degradation of stromal derived factor-1α (SDF-1α), which is the major chemokine responsible for mobilization and migration of stem cells to areas of ischemic injury.
More information about the clinical program is available by visiting the “clinicaltrials.gov” website at the following link: https://clinicaltrials.gov/ct2/show/NCT03486080
Recardio Inc. is a clinical-stage life science company focusing on regenerative therapies for cardiovascular diseases. The company’s lead drug candidate, dutogliptin, is a DPP-IV inhibitor that has demonstrated significant effects in activating SDF-1, a protein that is critical for cardiac regeneration. In addition to its current Phase 2 clinical program, Recardio will fully develop the therapeutic platform as a regenerative medication for patients with various cardiovascular diseases including acute myocardial infarction and chronic heart failure, with the potential of improving heart function, quality of life and survival. For more information, visit: http://www.recardio.eu/